The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,…
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire…
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a clinical trial TEL AVIV, Israel,…
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a…
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (“Rumi”), a developer of therapies for rare and neurodegenerative diseases…
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of…
Upon the closing which occurred on March 22, 2023, the purchase price was adjusted from $2.5 million and increased to…
Seventh ABA therapy center in the state meets growing need for high-quality, early intervention resources for young children with autismFREDERICK,…
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty…
TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical…